Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXENDA: Exenatide and Dapagliflozin in Type 2 Diabetes
NCT03007329Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2017
- Primary completion
- Nov 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of exenatide in type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), sponsored by Medical University of Vienna. Started Mar 2017; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03007329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007329.